Literature DB >> 8986820

Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates.

M Jansson1, M Popovic, A Karlsson, F Cocchi, P Rossi, J Albert, H Wigzell.   

Abstract

Primary HIV-1 isolates were evaluated for their sensitivity to inhibition by beta-chemokines RANTES (regulated upon activation, normal T-cell expressed and secreted), macrophage inflammatory protein 1 alpha (MIP-1 alpha), and MIP-1 beta. Virus isolates of both nonsyncytium-inducing (NSI) and syncytium-inducing (SI) biological phenotypes recovered from patients at various stages of HIV-1 infection were assessed, and the results indicated that only the isolates with the NSI phenotype were substantially inhibited by the beta-chemokines. More important to note, these data demonstrate that resistance to inhibition by beta-chemokines RANTES, MIP-1 alpha, and MIP-1 beta is not restricted to T cell line-adapted SI isolates but is also a consistent property among primary SI isolates. Analysis of isolates obtained sequentially from infected individuals in whom viruses shifted from NSI to SI phenotype during clinical progression exhibited a parallel loss of sensitivity to beta-chemokines. Loss of virus sensitivity to inhibition by beta-chemokines RANTES, MIP-1 alpha, and MIP-1 beta was furthermore associated with changes in the third variable (V3) region amino acid residues previously described to correlate with a shift of virus phenotype from NSI to SI. Of interest, an intermediate V3 genotype correlated with a partial inhibition by the beta-chemokines. In addition, we also identified viruses sensitive to RANTES, MIP-1 alpha, and MIP-1 beta of NSI phenotype that were isolated from individuals with AIDS manifestations, indicating that loss of sensitivity to beta-chemokine inhibition and shift in viral phenotype are not necessarily prerequisites for the pathogenesis of HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8986820      PMCID: PMC26413          DOI: 10.1073/pnas.93.26.15382

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

1.  HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain.

Authors:  W A O'Brien; Y Koyanagi; A Namazie; J Q Zhao; A Diagne; K Idler; J A Zack; I S Chen
Journal:  Nature       Date:  1990-11-01       Impact factor: 49.962

2.  Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection.

Authors:  B Asjö; L Morfeldt-Månson; J Albert; G Biberfeld; A Karlsson; K Lidman; E M Fenyö
Journal:  Lancet       Date:  1986-09-20       Impact factor: 79.321

3.  Rapidly and slowly replicating human immunodeficiency virus type 1 isolates can be distinguished according to target-cell tropism in T-cell and monocyte cell lines.

Authors:  S Schwartz; B K Felber; E M Fenyö; G N Pavlakis
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

4.  The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection.

Authors:  F Cocchi; A L DeVico; A Garzino-Demo; A Cara; R C Gallo; P Lusso
Journal:  Nat Med       Date:  1996-11       Impact factor: 53.440

5.  Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation.

Authors:  C Cheng-Mayer; M Quiroga; J W Tung; D Dina; J A Levy
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

6.  Simple, sensitive, and specific detection of human immunodeficiency virus type 1 in clinical specimens by polymerase chain reaction with nested primers.

Authors:  J Albert; E M Fenyö
Journal:  J Clin Microbiol       Date:  1990-07       Impact factor: 5.948

7.  Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates.

Authors:  M Tersmette; R A Gruters; F de Wolf; R E de Goede; J M Lange; P T Schellekens; J Goudsmit; H G Huisman; F Miedema
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

8.  CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication.

Authors:  C M Walker; D J Moody; D P Stites; J A Levy
Journal:  Science       Date:  1986-12-19       Impact factor: 47.728

9.  Human immunodeficiency virus type 1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristics.

Authors:  V A Sundqvist; J Albert; E Ohlsson; J Hinkula; E M Fenyö; B Wahren
Journal:  J Med Virol       Date:  1989-11       Impact factor: 2.327

10.  CD8+ T cells inhibit HIV replication in naturally infected CD4+ T cells. Evidence for a soluble inhibitor.

Authors:  J E Brinchmann; G Gaudernack; F Vartdal
Journal:  J Immunol       Date:  1990-04-15       Impact factor: 5.422

View more
  44 in total

1.  Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry?

Authors:  Y J Zhang; J P Moore
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  Higher macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels from CD8+ T cells are associated with asymptomatic HIV-1 infection.

Authors:  F Cocchi; A L DeVico; R Yarchoan; R Redfield; F Cleghorn; W A Blattner; A Garzino-Demo; S Colombini-Hatch; D Margolis; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

3.  Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry.

Authors:  M Cayabyab; S Hinuma; M Farzan; H Choe; S Fukusumi; C Kitada; N Nishizawa; M Hosoya; O Nishimura; T Messele; G Pollakis; J Goudsmit; M Fujino; J Sodroski
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  Sensitivity changes over the course of infection increases the likelihood of resistance against fusion but not CCR5 receptor blockers.

Authors:  Nikolaos Chatziandreou; Ana Belen Arauz; Ines Freitas; Phyu Hninn Nyein; Gregory Fenton; Shruti H Mehta; Gregory D Kirk; Manish Sagar
Journal:  AIDS Res Hum Retroviruses       Date:  2012-06-25       Impact factor: 2.205

5.  Do beta-chemokines have clinical relevance in HIV infection?

Authors:  C E Mackewicz; E Barker; G Greco; G Reyes-Teran; J A Levy
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

6.  CCR5 interactions with the variable 3 loop of gp120.

Authors:  Kelby B Napier; Zi-xuan Wang; Stephen C Peiper; John O Trent
Journal:  J Mol Model       Date:  2006-05-24       Impact factor: 1.810

Review 7.  Polyfunctional analysis of human t cell responses: importance in vaccine immunogenicity and natural infection.

Authors:  George Makedonas; Michael R Betts
Journal:  Springer Semin Immunopathol       Date:  2006-08-25

8.  Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype.

Authors:  A Björndal; H Deng; M Jansson; J R Fiore; C Colognesi; A Karlsson; J Albert; G Scarlatti; D R Littman; E M Fenyö
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

9.  Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolates.

Authors:  Ulf Karlsson; Liselotte Antonsson; Johanna Repits; Patrik Medstrand; Christer Owman; Karin Kidd-Ljunggren; Lars Hagberg; Bo Svennerholm; Marianne Jansson; Magnus Gisslén; Bengt Ljungberg
Journal:  AIDS Res Hum Retroviruses       Date:  2009-12       Impact factor: 2.205

10.  Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32.

Authors:  N L Michael; J A Nelson; V N KewalRamani; G Chang; S J O'Brien; J R Mascola; B Volsky; M Louder; G C White; D R Littman; R Swanstrom; T R O'Brien
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.